Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Personalized tremor control targeting for MR-guided focused ultrasound using tractography.

Brain communications·2026
Same author

Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions for disease elements in calcium pyrophosphate crystal deposition (CPPD).

Annals of the rheumatic diseases·2026
Same author

Correction to: Is Gout and Autoinflammatory Disease?

Current rheumatology reports·2026
Same author

Reflections on clinical academic promotions in contemporary times.

The American journal of the medical sciences·2026
Same author

Is Gout an Autoinflammatory Disease?

Current rheumatology reports·2026
Same author

Emotional Awareness and Expression Therapy for Migraine: A Preliminary Randomized Controlled Trial.

Pain medicine (Malden, Mass.)·2026

Related Experiment Video

Updated: Jul 3, 2026

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
15:09

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease

Published on: October 3, 2012

Uric acid in Parkinson's disease.

Ilana Schlesinger1, Naomi Schlesinger

  • 1Department of Neurology, Head, Movement Disorders Clinic, Rambam Health Care Campus, Haifa, Israel. i_schles@rambam.health.gov.il

Movement Disorders : Official Journal of the Movement Disorder Society
|July 12, 2008
PubMed
Summary

Higher serum urate (SU) levels may protect against Parkinson's disease (PD) development and progression. Lower SU levels were observed in PD patients, suggesting SU manipulation could be a potential therapeutic strategy for Parkinson's disease.

Related Experiment Videos

Last Updated: Jul 3, 2026

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
15:09

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease

Published on: October 3, 2012

Area of Science:

  • Neuroscience
  • Biochemistry
  • Epidemiology

Background:

  • Oxidative stress is implicated in Parkinson's disease (PD) pathogenesis.
  • Uric acid, a natural antioxidant, may mitigate oxidative stress.
  • Serum urate (SU) levels are being investigated for their role in neuroprotection.

Purpose of the Study:

  • To review the association between serum urate (SU) levels and Parkinson's disease (PD).
  • To explore the implications of SU levels in PD management and treatment.

Main Methods:

  • Literature review of studies examining uric acid and PD.
  • Analysis of the relationship between SU levels, PD risk, and disease progression.
  • Investigation of dietary and lifestyle factors influencing SU levels in PD.

Main Results:

  • Higher SU levels correlate with reduced PD risk and slower disease progression.
  • PD patients exhibit lower SU levels compared to control groups.
  • Dietary factors (e.g., purine intake, milk, meat) and exercise may influence SU levels and PD risk.

Conclusions:

  • Serum urate (SU) demonstrates a potential neuroprotective effect in Parkinson's disease (PD).
  • Modulating SU levels presents a promising avenue for PD treatment strategies.
  • Understanding the interplay between diet, lifestyle, and SU levels is crucial for PD management.